Human albumin solution utilization patterns prior and during COVID-19 pandemic in United Arab Emirates: Time to develop and implement national guideline on prescribing and utilization
Open Access
- 1 August 2022
- Vol. 2 (2)
- https://doi.org/10.52225/narra.v2i2.82
Abstract
The human albumin solution (HAS) has limited but important indications in clinical practice. However, the inappropriate use of HAS can be costly. Thus, it is imperative to establish a practical protocol to use albumin products and rationalize its usage. The aim of this study was to identify albumin utilization patterns in a multi-specialty private hospital in Dubai, United Arab Emirates (UAE), before and during the COVID-19 epidemic in the country. In addition, the objectives were to demonstrate the importance of reconsidering the prescribing strategies for albumin administration. All data on 20% HAS administration in Mediclinic Welcare Hospital were retrieved during January 2019–May 2021, including the total quantities administered and data on primary diagnosis. A total of 579 patient admissions with several diagnoses were included in the study. The percentage of clinically indicated 20% HAS administration decreased from 13.0% in the pre-COVID-19 phase to 1.5% in the COVID-19 phase (P<0.001). An increase in the administration of 20% HAS not backed by agreed clinical evidence followed the increase in new number of COVID-19 cases in the UAE. The current study showed a large proportion of administered HAS, that drastically increased during COVID-19 with lack of clear evidence of its benefit. This pilot study should be followed by refining of the institutional guidelines of HAS use, frequent audits and interactive educational interventions. In turn, the refinement of HAS administration guidelines can help to reduce the unjustified cost of inappropriate HAS use.This publication has 35 references indexed in Scilit:
- Human albumin solution for resuscitation and volume expansion in critically ill patientsEmergencias, 2011
- Impact of albumin compared to saline on organ function and mortality of patients with severe sepsisIntensive Care Medicine, 2010
- Resuscitation fluid use in critically ill adults: an international cross sectional study in 391 intensive care unitsCritical Care, 2010
- Recommendations for the use of albumin and immunoglobulins2009
- The clinical use of albumin: the point of view of a specialist in intensive care2009
- Albumin Therapy in Clinical PracticeNutrition in Clinical Practice, 2005
- Safety of human albumin—serious adverse events reported worldwide in 1998–2000 † †Declaration of interest. This investigation was supported by an unrestricted grant from the Plasma Protein Therapeutics Association. The sponsor played no role in the analysis and interpretation of data or the preparation and submission of the manuscript. Hygeia Associates is an independent organization specializing in the statistical analysis of biomedical research data and is in no way affiliated with the sponsor, either directly or indirectly. None of the co-investigators in this study has any conflict of interest to declare.British Journal of Anaesthesia, 2003
- Evaluation of the appropriate use of albumin in adult and pediatric patients.American Journal of Health-System Pharmacy, 2003
- Evaluation of human albumin use in a university hospital in Belgium.International Journal of Clinical Pharmacy, 2002
- Costs related to inappropriate use of albumin in Spain.2000